Clinical TrialMay 12, 2026, 07:38 AM
MiNK Therapeutics' agenT-797 shows dual immune action in cancer & ARDS
AI Summary
MiNK Therapeutics announced new data at ASGCT 2026 demonstrating that its allogeneic iNKT cell therapy, agenT-797, delivers context-dependent immune reprogramming. The same product showed TH1 pro-inflammatory activation in 34 solid tumor patients and TH2 anti-inflammatory benefits in 20 ARDS patients, without genetic engineering. Clinical activity included complete metastatic remission in oncology and improved survival in ARDS, supporting advancement into a randomized Phase 2 trial.
Key Highlights
- agenT-797 showed TH1 pro-inflammatory response in 34 solid tumor patients.
- agenT-797 showed TH2 anti-inflammatory response in 20 ARDS patients.
- Observed tumor clearance and durable response in cancer patients, including complete metastatic remission.
- Improved survival and radiographic resolution in ARDS patients, including pathogen clearance.
- Favorable safety profile observed across both oncology and ARDS settings.
- Data supports advancement into a randomized Phase 2 trial in acute lung injury.